Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) has announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share, as detailed in the company press release.
Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR) has announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share, as detailed in the company press release. All of the shares are being sold by Eiger. The gross proceeds to Eiger from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $49.5 million.
Latham & Watkins LLP represents the underwriters in the transaction with a corporate team led by Silicon Valley partner Brian Cuneo with associatesMiles Jennings, Michelle Lu and William Kirton. Advice was also provided by Silicon Valley associate Ashley Wagner on benefits and compensation; by San Francisco partner Grace Lee with Boston associate Jeremiah Cowen on tax matters; by Washington, D.C. partner Ben Haaswith San Francisco counsel Betty Pang and Washington, D.C. associates Robert Canning, Michael Dreyfuss and Barrett Tenbarge on regulatory matters; and by Silicon Valley/San Diego partner Chris Hazuka with Silicon Valley associate Gavin Liu on intellectual property matters.
